TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Thursday last week said that it expects sales in China to grow next year, when its oral formulation of antibiotic Taigexyn is to be included in China’s national medical insurance program.
TaiGen has agreed to cut the price of its Taigexyn by 46 percent to 16.2 yuan (US$2.30) from 30 yuan, which the company said was a mild discount compared with an average reduction of 60.7 percent for drugs to be included in the program.
“This result from negotiations signals that the [Chinese] National Healthcare Security Administration has a high opinion of our drug,” TaiGen chairman Philip Huang (黃國龍) said.
Although people in China have had to pay the full price for Taigexyn this year, demand has been robust, he said, adding that cumulative sales of the tablets have increased 1.7 times in the first three quarters of this year.
That growth is expected to accelerate next year as a total of 1.35 billion people in the insurance system would be able to use the drug, Huang said.
The potential market for Taigexyn is forecast to total 1 billion yuan per year in China, given that a rival treatment, Bayer AG’s Moxifloxacin, reported annual sales of at least 5 billion yuan, TaiGen said.
As for the intravenous formulation of Taigexyn, which TaiGen has said would be more popular and profitable than the oral version, the firm reiterated that it could start selling the drug in China next year, as it expects to gain marketing approval soon.
TaiGen shares advanced 4.15 percent to close at NT$21.35 in Taipei trading on Friday, compared with the Taipei Exchange’s decline of 0.81 percent, the exchange’s data showed.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
NO VIRUS BLUES: A SEMI Taiwan official said that the virus does not slow down the global semiconductor industry’s investment in manufacturing equipment The production value of the nation’s semiconductor industry is expected to grow 16.7 percent this year from last year, outpacing the global industry’s 3.3 percent growth, industry association SEMI said yesterday. That would help Taiwan safeguard its second spot in the global semiconductor market with a production value of more than NT$3 trillion (US$102.73 billion), SEMI Taiwan president Terry Tsao (曹世綸) told a media briefing in Taipei for the Semicon Taiwan trade show beginning today. The global semiconductor industry’s production value is expected to increase to US$426 billion this year, SEMI said. In terms of semiconductor equipment investment, equipment billings from Taiwanese firms
Intel Corp has received licenses from US authorities to continue supplying certain products to Huawei Technologies Co (華為), a company spokesman said yesterday. Washington has been pushing governments around to world to squeeze out Huawei, saying that the telecom giant would hand data to Beijing for espionage. From Monday last week, new curbs have barred US companies from supplying or servicing Huawei. This week, the state-backed China Securities Journal reported that Intel had received permission to supply Huawei. China’s Semiconductor Manufacturing International Corp (SMIC, 中芯國際), which uses US-origin equipment to make chips for Huawei and other companies, last week confirmed that it had sought
Merck Group Taiwan yesterday said that it plans to invest substantially on expanding its fab in Kaohsiung’s Lujhu District (路竹) to better serve its local customers, including Taiwan Semiconductor Manufacturing Co (TSMC, 台積電). The company said it plans to expand its production space by 50 percent in the next five years and its workforce by about 40 percent, Merck Group Taiwan managing director Dick Hsieh (謝志宏) told a media briefing in Taipei. Hsieh declined to disclose investment details, but said that the latest investment would exceed the total amount Merck has invested in Taiwan over the past few years. Those investments would be